TAI-1 is primarily used as a selective androgen receptor modulator (SARM) in research settings, focusing on its potential to promote muscle growth and bone density without the widespread androgenic effects seen with traditional steroids. It has drawn interest for its ability to target specific tissues, making it a candidate for studying treatments related to muscle wasting, osteoporosis, and other degenerative conditions. Due to its tissue-selective action, TAI-1 is investigated for therapeutic applications where preserving lean mass is critical, such as in aging populations or patients undergoing chronic illness. It is not approved for human use and remains strictly for preclinical research.